Partner responsible: PALOBIOFARMA SL
Partners involved: the entire consortium
In recent years there has been a breakthrough in the development of cancer treatments “chemotherapy-free”. In this context, immunotherapy is a type of cancer treatment designed to stimulate the patient’s immune system in a way that recognizes and combats the tumor. Among the most developed types of immunotherapies are monoclonal antibodies, which are drugs designed to bind specifically to key cells of the immune system or the tumor itself. In this sense, antibodies against CTLA-4 or PD-1 allow neutralizing these inhibitor molecules and triggering the immune response against the tumor. However, the tumor has developed other strategies to regulate negatively the anti-tumor response, highlighting the generation of the adenosine metabolite, with great immunosuppressive activity, which is presented at high concentrations in the tumor microenvironment. For this reason the new tendencies in immunotherapy propose combined therapies. These new targets are beginning to be explored with great success in cancers of solid tumors, but their potential in hematological cancers is still to be explored and confirmed.
IMLINFO has the following activities planned:
- Synthesis of adenosine receptor inhibitors.
- Study of effectiveness and mechanism of action.
- Proof-of-concept trial in patients with NHL.